Atlas Trials

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

Clinical trial NCT03841448 · TERMINATED

Trial details

NCT number
NCT03841448
Sponsor
Alnylam Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
IgA Nephropathy (IgAN)Berger DiseaseGlomerulonephritis, IgA
Start date
2019-09-30
Primary completion
2022-03-17
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.